BRCA1 and Estrogen Receptor α Expression Regulation in Breast Cancer Cells
- Authors: Scherbakov A.M.1, Shestakova E.A.1, Galeeva K.E.1, Bogush T.A.1
-
Affiliations:
- Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- Issue: Vol 53, No 3 (2019)
- Pages: 442-451
- Section: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/163973
- DOI: https://doi.org/10.1134/S0026893319030166
- ID: 163973
Cite item
Abstract
BRCA1 (breast cancer 1) protein is involved in the genome stability maintenance participating in homologous recombination-dependent DNA repair. Disruption of BRCA1 functioning is associated with breast and ovarian cancer. Despite the important role of BRCA1 in DNA repair in all cell types, the development of BRCA1-associated cancer takes place mainly in estrogen-dependent tissues such as breast and ovarian ones. Using breast cancer cell line MCF-7 it was demonstrated in in vitro experiments that the estrogen 17β-estradiol (E2), phytoestrogens (genistein and apigenin) and antiestrogens (tamoxifen and fulvestrant) inhibited estrogen receptor α (ERα) expression while only genistein influenced BRCA1 increasing its expression. In hypoxia, that is an important factor of solid tumors progression, the decrease of BRCA1 and ERα expression was demonstrated in MCF-7 cells. Therefore, hypoxia influences both BRCA1-dependent DNA repair and hormonal regulation of breast cancer cell growth. Taken together, obtained results demonstrate a relationship between BRCA1 and steroid hormones signal transduction pathways in breast cancer cells and point out to the importance of complex BRCA1 and ERα expression regulation mechanisms studies including epigenetic gene expression regulation.
About the authors
A. M. Scherbakov
Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: elenaanshestakova@mail.ru
Russian Federation, Moscow, 115478
E. A. Shestakova
Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: elenaanshestakova@mail.ru
Russian Federation, Moscow, 115478
K. E. Galeeva
Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: elenaanshestakova@mail.ru
Russian Federation, Moscow, 115478
T. A. Bogush
Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: elenaanshestakova@mail.ru
Russian Federation, Moscow, 115478
Supplementary files
